GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans

Key Findings

🔬 Women lose more weight than men on GLP-1 drugs

• Analysis of 64 clinical trials found women lost 10.9% of their body weight on GLP-1 drugs compared to 6.8% for men

• The difference held across age groups, ethnicities, and baseline weights, suggesting biological sex influences drug response

• No other patient characteristics—including age, race, or starting weight—significantly affected how well the drugs worked

💡 New triple-action drug shows promise for massive weight loss

• Retatrutide, which targets three hormone receptors instead of one, helped people lose up to 26.56% of their body weight in trials

• The drug outperformed existing GLP-1 medications, with some patients losing over 50 pounds in clinical studies

• Meta-analysis of 14 trials showed retatrutide had the strongest weight loss effects, followed by survodutide and mazdutide

🎯 GLP-1 drugs may prevent alcohol-related liver damage

• Patients with diabetes and alcohol use disorders who took GLP-1 drugs had 32% lower risk of developing cirrhosis compared to those on other diabetes medications

• The protective effect was strongest when compared to insulin users, with 67-78% lower risk of liver complications

• Benefits appeared in both obese and non-obese patients, suggesting effects beyond just weight loss

🧪 Brain circuits controlling meal size may be key to obesity

• Researchers identified specific brain neurons in mice that determine when to stop eating during meals

• Mice with fewer of these satiety neurons gained more weight, and their total number inversely correlated with weight gain

• Artificially activating these neurons caused sustained weight loss in obese mice without apparent side effects

📊 Rural patients less likely to receive GLP-1 drugs for sleep apnea

• Among 68,680 veterans with sleep apnea and excess weight, rural residents were 10% less likely to receive GLP-1 medications

• The disparity wasn't explained by distance to care or drive time to medical facilities

• Only 8% of all patients received GLP-1 drugs despite their potential benefits for both weight loss and sleep apnea

🔬 Dangerous case highlights risks for post-surgery patients

• A patient who had gastric bypass surgery developed life-threatening malnutrition and liver injury after starting semaglutide

• The combination of altered gut anatomy and GLP-1 effects created a "dual-hit" that required ICU care and reversal of the original surgery

• Case highlights need for careful monitoring when GLP-1 drugs are used in patients with previous bariatric procedures